RhumbLine Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Hold |
|
|||||
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $63.3K | Sell |
|
|||||
|
2024
Q4 | $113K | Buy |
|
|||||
|
2024
Q3 | $229K | Sell |
|
|||||
|
2024
Q2 | $257K | Buy |
|
|||||
|
2024
Q1 | $324K | Buy |
|
|||||
|
2023
Q4 | $199K | Hold |
|
|||||
|
2023
Q3 | $142K | Sell |
|
|||||
|
2023
Q2 | $320K | Buy |
|
|||||
|
2023
Q1 | $304K | Buy |
|
|||||
|
2022
Q4 | $228K | Buy |
|
|||||
|
2022
Q3 | $272K | Buy |
|
|||||
|
2022
Q2 | $181K | Buy |
|
|||||
|
2022
Q1 | $167K | Sell |
|
|||||
|
2021
Q4 | $341K | Buy |
|
|||||
|
2021
Q3 | $404K | Buy |
|
|||||
|
2021
Q2 | $375K | Buy |
|
|||||
|
2021
Q1 | $323K | Sell |
|
|||||
|
2020
Q4 | $194K | Buy |
|
|||||
|
2020
Q3 | $72K | Sell |
|
|||||
|
2020
Q2 | $129K | Buy |
|
|||||
|
2020
Q1 | $110K | Sell |
|
|||||
|
2019
Q4 | $249K | Buy |
|
|||||
|
2019
Q3 | $177K | Sell |
|
|||||
|
2019
Q2 | $372K | Buy |
|
|||||
|
2019
Q1 | $309K | Sell |
|
|||||
|
2018
Q4 | $380K | Buy |
|
|||||
|
2018
Q3 | $414K | Sell |
|
|||||
|
2018
Q2 | $499K | Buy |
|
|||||
|
2018
Q1 | $345K | Sell |
|
|||||
|
2017
Q4 | $411K | Sell |
|
|||||
|
2017
Q3 | $624K | Buy |
|
|||||
|
2017
Q2 | $815K | Buy |
|
|||||
|
2017
Q1 | $682K | Buy |
|
|||||
|
2016
Q4 | $640K | Buy |
|
|||||
|
2016
Q3 | $771K | Buy |
|
|||||
|
2016
Q2 | $602K | Sell |
|
|||||
|
2016
Q1 | $632K | Buy |
|
|||||
|
2015
Q4 | $658K | Buy |
|
|||||
|
2015
Q3 | $513K | Buy |
|
|||||
|
2015
Q2 | $377K | Buy |
|
|||||
|
2015
Q1 | $250K | Buy |
|
|||||
|
2014
Q4 | $198K | Buy |
|
|||||
|
2014
Q3 | $296K | Sell |
|
|||||
|
2014
Q2 | $338K | Sell |
|
|||||
|
2014
Q1 | $365K | Sell |
|
|||||
|
2013
Q4 | $400K | Sell |
|
|||||
|
2013
Q3 | $542K | Buy |
|
|||||
|
2013
Q2 | $490K | Buy |
|